A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life.
Incyte is ‘optimistic’ about skin disease drug Opzelura as prescriptions grow 77% in Q4
Incyte expects its atopic dermatitis and vitiligo treatment Opzelura to be a “key contributor” to growth in 2024 after sales jumped 78% in the fourth